Roche Finance Europe B.V., founded in 2005 and headquartered in the Netherlands, serves as a key financing entity for the Roche Group, a global leader in pharmaceuticals and diagnostics. The company primarily focuses on issuing debt securities to support the Group's strategic initiatives and enhance its financial flexibility.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ROSW 3.20% 2029-08-27 EURRoche Finance Europe B.V. | Netherlands | 2029-08-27 | 3.204 | 2.54 |
| ROSW 3.23% 2030-05-03 EURRoche Finance Europe B.V. | Netherlands | 2030-05-03 | 3.227 | 2.57 |
| ROSW 3.31% 2027-12-04 EURRoche Finance Europe B.V. | Netherlands | 2027-12-04 | 3.312 | 2.41 |
| ROSW 3.36% 2035-02-27 EURRoche Finance Europe B.V. | Netherlands | 2035-02-27 | 3.355 | 3.10 |
| ROSW 3.56% 2044-05-03 EURRoche Finance Europe B.V. | Netherlands | 2044-05-03 | 3.564 | 3.82 |
| ROSW 3.59% 2036-12-04 EURRoche Finance Europe B.V. | Netherlands | 2036-12-04 | 3.586 | 3.51 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Roche Finance Europe has actively participated in the bond market, debuting its bond issuances in 2006. Notably, in 2020, the company launched a significant €1 billion bond to finance research and development projects related to COVID-19, reflecting its commitment to addressing global health challenges. The current yields of its bonds remain competitive within the industry, buoyed by the company's robust credit rating and established reputation.